Abstract
The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn’s disease has been evaluated. Thirty-two patients with Crohn’s disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn’s disease. However, in view of the product’s cost, further controlled studies are needed to confirm these preliminary data.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, D'Albasio G, DeSimone G, Martini N: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 89:692–698, 1994
Steinhart AH, Hemphill D, Greenberg GR: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: A meta-analysis. Am J Gastroenterol 89:2116–2124, 1994
De Franchis R, Omodei P, Ranzi T, Brignola C, Rocca R, Prada A, Pera A, Vecchi M, Del Piano M, Ferrara A, Belloli C, Piodi L, Framarin L, Astegiano M, Riccioli FA, Meucci G: Controlled trial of oral 5-aminosalycilic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 11:845–852, 1997
Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M: Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 103:363–368, 1992
Rutgeerts P, Ghoos Y, Van Trappen E: Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease. Eur J Clin Invest 11:199–206, 1981
Chiodini RJ: Antimicrobial agents and Crohn's disease: Do they have a therapeutic role? Ital J Gastroenterol Hepatol 30:593–598, 1998
Spirt MJ: Antibiotics in inflammatory bowel disease: New choices for an old disease. Am J Gastroenterol 89:974–978, 1994
Bengmark S: Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 42:2–7, 1988
Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C: Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67:302–307, 1999
Dias RS, Bambirra EA, Silva ME, Nicoli JR: Protective effect of Saccharomyces boulardii against the cholera toxins in rats. Braz J Med Biol Res 28:323–325, 1995
McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271:1913–1918, 1994
Bleichner G, Blehaut H, Mentec H, Moyse D: Saccharomyces boulardii prevents diarrhea in crically ill tube-fed patients. A multicenter, randomized double-blind placebo-controlled trial. Intens Care Med 23:517–523, 1997
Kimmey KB, Elmer GW, Surawicz CM, McFarland LV: Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci 35:897–901, 1990
Plein K, Hotz J: Therapeutic effects of Saccharomices boulardii on mild residual symptoms in a stable phase of Crohn's disease with special resopect to chronic diarrhea-a pilot study. Z Gastroenterol 31:129–134, 1993
Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R: Response of human and rat small intrestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20:192–196, 1986
Buts JP, Bernasconi P, Vaerman JP, Dive C: Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35:251–256, 1990
Izadnia F, Wong CT, Kocoshis SA: Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat. Dig Dis Sci 43:2055–2060, 1998
Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D: Anti-Saccharomyces cerevisiae mannan combined with antineutrophil antibodies in inflammatory bowel disease. Prevalence and diagnostic role. Gut 42:788–791, 1998
Sendid B, Quinton JF, Charrier G, Goulet O, Cortot A, Grandbastien B, Poulain D, Colombel JF: Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 93:1306–1310, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guslandi, M., Mezzi, G., Sorghi, M. et al. Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease. Dig Dis Sci 45, 1462–1464 (2000). https://doi.org/10.1023/A:1005588911207
Issue Date:
DOI: https://doi.org/10.1023/A:1005588911207